Skip to content
DraconiticResearch
Search Sources API
203,234 studies31 sourcesUpdated 38 min ago
Peer-reviewedCC BY 4.0Frontiers in Immunology

Cellular senescence in multiple sclerosis: hallmarks, immunosenescence, and therapeutic implications

  • Ala’ Yousef1,2
  • John M. Seubert3,4
  • Christopher Power1,2
  • Nabeela Nathoo1,2
4 affiliations
  1. 1Department of Medicine (Neurology), Faculty of Medicine and Dentistry, University of Alberta
  2. 2Multiple Sclerosis Centre, University of Alberta
  3. 3Faculty of Pharmacy and Pharmaceutical Sciences, University of Alberta
  4. 4Department of Pharmacology, Faculty of Medicine and Dentistry, University of Alberta
Read full textPDFDOICite

Abstract

Multiple sclerosis (MS) is an immune-mediated neurodegenerative disease where chronological aging predicts the conversion to progressive MS (PMS), a phase defined by compartmentalized inflammation and accelerated neurodegeneration. While current disease modifying therapies (DMTs) are effective for managing the inflammatory aspect of MS, treatments remain inadequate. It is imperative to understand the biology of aging including an important hallmark of aging, cellular senescence. Cellular senescence is a state of cell cycle arrest where cells remain in their senescent state and produce a distinctive senescence-associated secretory phenotype (SASP), characterized by the release of pro-inflammatory cytokines, chemokines, and growth factors. Growing experimental and clinical evidence suggests that the accumulation of senescent cells and SASP secretion perpetuates a pathological feedback loop linking age-related processes with accelerated neurodegeneration observed in PMS. Whether senescence drives PMS or accompanies it remains unresolved. In this Review, we outline the biology of aging, senescence pathway markers, and SASP components. We evaluate studies of cellular senescence and SASP markers in MS, including immunosenescence, T- and B-cell changes; the contributions of Epstein-Barr virus, cytomegalovirus, and herpes simplex virus-1; and the relationship between senescence burden, brain atrophy, and DMT response. Lastly, we outline the available senotherapeutic approaches aimed at mitigating MS and other neurodegenerative diseases.

Related

  1. Tree Shrew as an Emerging Model for Aging Research: Characterization of Senescence and Therapeutic Interventions
    Qiuni Luo, Wenxian Xiao, Xin Dong +18
    Aging CellPeer-reviewedCC BY 4.0Full textCell biologyPMC
  2. Conceptual framework for the definition of disease modification in systemic sclerosis and potential implications for drug development and clinical study design
    Jörg Distler, Shervin Assassi, Armando Gabrielli +33
    Annals of the Rheumatic DiseasesPeer-reviewedCC BY 4.0Full textImmunologyHAL
  3. Dendritic cell diversity and dysfunction in cancer: implications for immunotherapy and therapeutic targeting
    Rong Wang, Yi Chen, Yan-fen Fang
    Acta Pharmacologica SinicaPeer-reviewedLicence not statedFull text2 citedImmunologyPMC
  4. Editorial: The expanding spectrum of hemophagocytic lymphohistiocytosis: pathogenic mechanisms and therapeutic implications
    Tiziana Lorenzini, Ola Sabet, Yasmine El Chazli +2
    Frontiers in ImmunologyPeer-reviewedCC BY 4.0Full textImmunologyCrossref
  5. Hyperinflammation and immunomodulation in influenza, SARS-CoV-2 and syncytial respiratory virus infection in adults: from innate immune responses and biomarkers to clinical and therapeutic implications
    Jesus Alonso-Carrillo, Marta Obra, Mario Cereza +3
    Frontiers in microbiologyPeer-reviewedCC BYFull textMicrobiologyEurope PMC

Cite

BibTeXRIS
BibTeX
@article{yousef2026cellular,
  title = {{Cellular senescence in multiple sclerosis: hallmarks, immunosenescence, and therapeutic implications}},
  author = {Ala’ Yousef and John M. Seubert and Christopher Power and Nabeela Nathoo},
  journal = {Frontiers in Immunology},
  year = {2026},
  month = oct,
  doi = {10.3389/fimmu.2026.1944657},
  url = {https://www.frontiersin.org/articles/10.3389/fimmu.2026.1944657/full},
  note = {CC BY 4.0},
}
RIS
TY  - JOUR
TI  - Cellular senescence in multiple sclerosis: hallmarks, immunosenescence, and therapeutic implications
AU  - Ala’ Yousef
AU  - John M. Seubert
AU  - Christopher Power
AU  - Nabeela Nathoo
PY  - 2026
DA  - 2026/10/07
JO  - Frontiers in Immunology
DO  - 10.3389/fimmu.2026.1944657
UR  - https://www.frontiersin.org/articles/10.3389/fimmu.2026.1944657/full
AB  - Multiple sclerosis (MS) is an immune-mediated neurodegenerative disease where chronological aging predicts the conversion to progressive MS (PMS), a phase defined by compartmentalized inflammation and accelerated neurodegeneration. While current disease modifying therapies (DMTs) are effective for managing the inflammatory aspect of MS, treatments remain inadequate. It is imperative to understand the biology of aging including an important hallmark of aging, cellular senescence. Cellular senescence is a state of cell cycle arrest where cells remain in their senescent state and produce a distinctive senescence-associated secretory phenotype (SASP), characterized by the release of pro-inflammatory cytokines, chemokines, and growth factors. Growing experimental and clinical evidence suggests that the accumulation of senescent cells and SASP secretion perpetuates a pathological feedback loop linking age-related processes with accelerated neurodegeneration observed in PMS. Whether senescence drives PMS or accompanies it remains unresolved. In this Review, we outline the biology of aging, senescence pathway markers, and SASP components. We evaluate studies of cellular senescence and SASP markers in MS, including immunosenescence, T- and B-cell changes; the contributions of Epstein-Barr virus, cytomegalovirus, and herpes simplex virus-1; and the relationship between senescence burden, brain atrophy, and DMT response. Lastly, we outline the available senotherapeutic approaches aimed at mitigating MS and other neurodegenerative diseases.
SN  - 1664-3224
ER  -